Protalix BioTherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	61.84	53.4	65.49	47.64	38.35	62.9
Revenue Growth (YoY)	35.41%	-18.47%	37.48%	24.22%	-39.03%	15.00%
Cost of Revenue	26.26	24.32	22.98	19.59	16.35	10.87
Gross Profit	35.58	29.08	42.51	28.05	22	52.03
Selling, General & Admin	11.16	12.19	14.96	11.71	12.73	11.15
Research & Development	18.06	12.97	17.09	29.35	29.73	38.17
Operating Expenses	29.21	25.16	32.05	41.06	42.46	49.32
Operating Income	6.37	3.92	10.46	-13.01	-20.46	2.71
Interest Expense	-0.81	-1.06	-3.18	-2.53	-7.52	-9.67
Interest & Investment Income	0.93	1.3	1.29	1.15	0.4	0.44
EBT Excluding Unusual Items	6.48	4.15	8.57	-14.4	-27.58	-6.52
Pretax Income	6.48	4.15	8.57	-14.4	-27.58	-6.52
Income Tax Expense	1.09	1.22	0.25	0.53	-	-
Earnings From Continuing Operations	5.39	2.93	8.31	-14.93	-27.58	-6.52
Net Income	5.39	2.93	8.31	-14.93	-27.58	-6.52
Net Income to Common	5.39	2.93	8.31	-14.93	-27.58	-6.52
Net Income Growth	-	-64.73%	-	-	-	-
Shares Outstanding (Basic)	76	73	68	48	44	29
Shares Outstanding (Diluted)	85	81	82	48	44	29
Shares Change (YoY)	15.89%	-1.66%	70.04%	9.81%	51.43%	96.44%
EPS (Basic)	0.07	0.04	0.12	-0.31	-0.62	-0.22
EPS (Diluted)	0.07	0.04	0.09	-0.31	-0.62	-0.22
EPS Growth	-	-57.71%	-	-	-	-
Free Cash Flow	-11.69	7.39	-2.47	-25.63	-11.74	-26.76
Free Cash Flow Per Share	-0.14	0.09	-0.03	-0.53	-0.27	-0.92
Gross Margin	57.54%	54.46%	64.91%	58.87%	57.37%	82.71%
Operating Margin	10.30%	7.33%	15.97%	-27.32%	-53.36%	4.31%
Profit Margin	8.72%	5.49%	12.69%	-31.33%	-71.92%	-10.37%
Free Cash Flow Margin	-18.91%	13.84%	-3.77%	-53.80%	-30.62%	-42.55%
EBITDA	7.78	5.22	11.65	-11.93	-19.34	4.01
EBITDA Margin	12.58%	9.78%	17.79%	-25.04%	-50.44%	6.38%
D&A For EBITDA	1.41	1.3	1.19	1.09	1.12	1.3
EBIT	6.37	3.92	10.46	-13.01	-20.46	2.71
EBIT Margin	10.30%	7.33%	15.97%	-27.32%	-53.36%	4.31%
Effective Tax Rate	16.81%	29.42%	2.96%	-	-	-
Revenue as Reported	61.84	53.4	65.49	47.64	38.35	62.9

Updated Nov 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q